source
- Merck licenses KRAS G12D inhibitor from Tao Hu for $400 million upfrontMerck has signed a licensing agreement for a KRAS G12D inhibitor, providing an upfront payment of $400 million. The deal follows a 2023 transaction in which the same entrepreneur, synthetic chemis…
- AbbVie’s once-daily Parkinson’s pill receives FDA approvalAbbVie announced that the U.S. Food and Drug Administration has granted approval for its once‑daily oral therapy for Parkinson’s disease. The decision allows the product to be marketed in the Unite…